Last reviewed · How we verify
HW201877 capsules — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HW201877 capsules (HW201877 capsules) — Wuhan Humanwell Innovative Drug Research and Development Center Limited Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HW201877 capsules TARGET | HW201877 capsules | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HW201877 capsules CI watch — RSS
- HW201877 capsules CI watch — Atom
- HW201877 capsules CI watch — JSON
- HW201877 capsules alone — RSS
Cite this brief
Drug Landscape (2026). HW201877 capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/hw201877-capsules. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing